



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/NTR

Review Article

Probiotics: A potential immunomodulator in COVID-19 infection management

Kuljit Singh^{a,#}, Alka Rao^{a,b,*}^a CSIR-Institute of Microbial Technology, Sector 39A, Chandigarh 160036 India^b Academy of Scientific and Innovation Research (AcSIR), Ghaziabad, Uttar Pradesh 201002 India

ARTICLE INFO

Article history:

Received 1 June 2020

Revised 2 December 2020

Accepted 15 December 2020

Keywords:

COVID-19

Influenza virus

Lactobacillus

Probiotics

Respiratory viral infection

SARS-CoV-2

ABSTRACT

COVID-19 caused by SARS-CoV-2 is an ongoing global pandemic. SARS-CoV-2 affects the human respiratory tract's epithelial cells, leading to a proinflammatory cytokine storm and chronic lung inflammation. With numerous patients dying daily, a vaccine and specific antiviral drug regimens are being explored. Probiotics are live microorganisms with proven beneficial effects on human health. While probiotics as nutritional supplements are long practiced in different cuisines across various countries, the emerging scientific evidence supports the antiviral and general immune-strengthening health effects of the probiotics. Here, we present an overview of the experimental studies published in the last 10 years that provide a scientific basis for unexplored probiotics as a preventive approach to respiratory viral infections. Based on collated insights from these experimental data, we identify promising microbial strains that may serve as lead prophylactic and immune-boosting probiotics in COVID-19 management.

© 2020 Elsevier Inc. All rights reserved.

1. Introduction

Coronavirus disease 2019 (COVID-19) is a severe respiratory inflammatory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is declared a global pandemic by the World Health Organization (WHO) [1]. Unfortunately, even after implementing various strategic and socioeconomic response plans and stringent public health measures globally, including personal hygiene, mask-wearing,

social distancing, lockdowns, and quarantines, the number of infections and death are on the rise. The WHO assessment is that the disease may continue to stay with the population. It requires constant preparedness and investment in public health and other resources to manage the spread and morbidity caused by SARS-CoV-2.

SARS-CoV-2 is a new and different virus from previously known coronaviruses, namely Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV [2]. Therefore, the existing antiviral or flu vaccines are not effective against

Abbreviations: ACE2, Angiotensin-converting enzyme 2; COVID-19, Coronavirus disease; CRP, C-reactive protein; GCSF, Granulocyte colony-stimulating factor; IFV, influenza A virus; IL, Interleukin; IFN- γ , Interferon-gamma; MERS-CoV, Middle East respiratory syndrome coronavirus; NK, Natural killer; OAS, Oligoadenylate synthetase; RVI, Respiratory virus infections; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; TNF, Tumor Necrosis Factor; Th1/2, T-helper cells type 1 and 2; WHO, World Health Organization.

* Corresponding author at: CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh 160036 India.

E-mail address: raoalka@imtech.res.in (A. Rao).

Present Address: CSIR-Indian Institute of Integrative Medicine, Jammu, 180001, India.

<https://doi.org/10.1016/j.nutres.2020.12.014>

0271-5317/© 2020 Elsevier Inc. All rights reserved.

it. With a constant boost from WHO, several research and development efforts are going on at the international level to develop the specific therapy and vaccine against the new virus [3]. The clinical use of Hydroxychloroquine, Lopinavir/Ritonavir, Remdesivir, anti-inflammatory drugs, convalescent plasma, anticoagulants, Vasodilators, nonsteroidal anti-inflammatory drugs, and monoclonal antibodies is under different stages of trials, research, or approvals. Nevertheless, no treatment so far is precise to the virus [4–7]. While such medicines and vaccines are not available, the virus is already mutating and manifesting in symptomatic, presymptomatic, and asymptomatic forms in affected populations. In symptomatic cases, the common COVID-19 indications include fever, tiredness, dry cough, nasal congestion, diminished sense of smell, sore throat, body pains, and gut dysbiosis [8,9].

With disease onset, the patient faces difficulty in breathing, and in due course, the disease progresses into severe respiratory tract infection and chronic inflammation [10]. Such condition may precede a presymptomatic condition that ranges from a week to a fortnight with heavy viral loads and a high risk of spreading the coronavirus to others. Similarly, the infected yet asymptomatic population serves as the carrier and transmits the virus to people without symptoms. Both presymptomatic and asymptomatic manifestations are indeed one of the primary reasons for the pandemic. At the cellular level, immunomodulatory markers such as proinflammatory cytokines, Interleukin (IL)-1 β , IL-2, IL-6, IL-7, IL-12, tumor necrosis factor (TNF)- α , interferon-gamma (IFN- γ) and anti-inflammatory cytokines IL-4, IL-10, IL-11, and IL-13 control the infection. Further, natural killer (NK) cells, cytotoxic T-lymphocytes, and antibody production also play a crucial role in promoting pathogen killing [11,12].

Probiotics are nonpathogenic living microorganisms providing various health benefits to the human host. The common probiotic strains belong to the genera of *Lactobacillus* and *Bifidobacterium*. The use of probiotics in food such as fermented food is traditional knowledge and ascertained to improve nutrition and health by restoring microbial balance in the human gut [13]. Interestingly, in the last 2 decades, several studies have demonstrated the role of probiotics in managing immune responses and various disease conditions, specifically viral infections in different animal models and clinical trials. Studies suggest that dietary meals with fiber and probiotics supplementation support a stable host immune response system, preventing adverse effects of viral infections [14,15]. Various studies have reported the beneficial role of probiotic bacteria, namely, *Lactobacillus plantarum* [16], *Bacillus subtilis* [17], *Lactobacillus casei* [18], *Lactobacillus plantarum* [19], and *Bifidobacterium bifidum* [20] in experimental animal models of respiratory tract viral infection. Probiotic interventions led to improved animal health, easing clinical symptoms, lowering viral load in the lungs, and enhanced survival rates were observed [21].

Therefore, we first used a list of keywords (probiotics, virus, influenza virus, antiviral, respiratory tract infections, gut dysbiosis, microbial strain names, animal model, etc.) and their combinations to search PubMed, Science Direct, and Google Scholar. In this manner, we retrieved ~4500 experimental studies published on the subject between 2010 and 2020. Next,

we collated and discussed the published experimental evidence of probiotics efficacy in preventing viral infections. We evaluated the insights gleaned from these studies in the SARS-CoV-2 infection scenario. Finally, we list the probiotic strains that may lead to preventive interventions and general immunity enhancers to manage COVID-19 and related viral infections.

2. Probiotics as antiviral agents

The human respiratory tract is exposed to several microorganisms. It is the primary path for the internalization of respiratory viruses. Thus, preventing the virus's adsorption onto the mucosal epithelial surfaces is crucial for reducing disease development. The human body harbors a range of mutually beneficial microorganisms. Collectively, we denote them as the human microbiota. Probiotics are also one such friendly set of microbes that positively influence human health when ingested or administered in a particular concentration. Probiotic strains of *Lactobacillus* and *Bifidobacterium* genera can trap the virus and interfere in the virus binding to the host cell receptors, which is beneficial to the host health [22,23]. Similarly, probiotics administration confers health benefits to humans against respiratory viral infections, including Respiratory syncytial virus and Influenza A virus (IFV) [15]. Here we discuss and compare (in Table 1) several of these experimental studies published since 2010 that have characterized probiotics as antiviral agents against different viruses using various animal models and clinical studies on human subjects.

2.1. Preclinical studies in animal models

We observe that most preclinical studies have employed *Lactobacillus* and *Bifidobacterium* strains to evaluate their antiviral effect. The experimental design of most studies discussed below included administering probiotic strains, followed by infection with the virus. Here, we have discussed them in the order of year of reporting.

Using IFV in a mice model, Kawashima's group [16] evaluated the antiviral effects of *L. plantarum* YU strain. Administration of probiotic strain steered weight loss and virus proliferation in the lungs and bronchoalveolar lavage fluids in a dose-dependent manner. Probiotic strain activated the T-helper cells type 1 (Th1) immune response, which resulted in increased levels of IFV-specific secretory IgA and neutralizing antibody titers in bronchoalveolar lavage fluids and sera, respectively, which led to the removal of IFV from lungs and other infected sites. These results confirm that the administration of probiotics strain has a protective role against IFV infection.

Song's group [24] conducted a study to analyze the antiviral efficacy of *L. rhamnosus* against IFV infection. There was a significant difference in mice's survival rate after administration of live and dead *L. rhamnosus* bacteria via both oral and intranasal routes. Dosage of live and dead probiotic bacteria via oral route led to survival rates of 40% and 0%. In contrast, the survival rate in the intranasal route was 70% and 40%, respectively. In both cases, the survival rate was higher with the administration of live bacteria. Treatment with live bacteria

Table 1 – List of probiotic strains and preclinical and clinical evidences of their efficacy in managing viral diseases

Probiotic strains	Study year	Infection	Model	Outcomes	Ref.
<i>Lactobacillus pentosus</i> S-PT84	2010	Influenza virus A/PR/8/34 (H1N1)	Female BALB/c mice	Higher survival rate and lower viral load in lungs along with increased NK cells activity along with a higher expression of IL-12 and IFN- α in the lung tissue	[59]
<i>Lactobacillus rhamnosus</i> GG and <i>Lactobacillus gasseri</i> TMC0356	2010	Influenza virus A/PR/8/34 (H1N1)	Female BALB/c mice	Alleviate clinical symptoms and significantly lower virus load in the lungs of infected mice.	[60]
<i>Lactobacillus plantarum</i> YU	2011	Influenza virus A/NWS/33 (H1N1)	Male BALB/c mice	Prevented weight loss and suppressed viral proliferation due to enhanced Th1 immune response	[16]
<i>Lactobacillus pentosus</i> strain b240	2011	Influenza virus A/PR/8/34 (H1N1)	Female BALB/c mice	Increased survival rate and lower virus load in the lungs along with increased production of IgA and IgG in bronchoalveolar lavage fluid and plasma	[61]
<i>Bifidobacterium lactis</i> Bb-12	2011	Respiratory tract infections	Clinical trial 109 participants	Newborn infants receiving probiotics had a lower (65%) incidence of respiratory infections as compared to 94% of infants in the control group	[44]
<i>Lactobacillus rhamnosus</i>	2012	Influenza virus A/NWS/33 (H1N1)	Female BALB/c mice	The increased survival rate with intranasal dosage along with increased secretory IgA production and reduced the expression levels of TNF- α and IL-6	[24]
<i>Lactobacillus reuteri</i> ATCC 55730	2012	Inflammatory bowel diseases	Clinical trial 40 participants	Useful in improving mucosal inflammation along with increased cytokine expression level of IL-10 and decreased levels of TNF- α , IL-1 β , and IL-8	[53]
<i>Lactobacillus plantarum</i> CNRZ1997	2013	Influenza virus A/PR/8/34 (H1N1)	Female BALB/c mice	Reduced weight loss, alleviated clinical symptoms, and decreased virus load in the lungs of infected mice	[25]
<i>Lactobacillus plantarum</i> LBP-K10	2013	Influenza virus H3N2	Madin-Darby canine kidney cells	Cyclic dipeptides obtained from culture filtrate was successful in inhibiting viral infectivity and proliferation	[62]
<i>Lactobacillus acidophilus</i> L-92	2013	Influenza virus A/PR/8/34 (H1N1)	Female BALB/c mice	Prevented weight loss, reduced viral load in the lungs along with an increased expression of antiviral cytokines and chemokines	[26]
<i>Lactobacillus rhamnosus</i> GG and <i>Bifidobacterium lactis</i> Bb-12	2013	Upper respiratory tract infection	Clinical trial 231 participants	The severity of upper respiratory infections was lower in the probiotic group along with the improved quality of life	[49]
<i>Bifidobacterium infantis</i> 35624	2013	Inflammatory bowel diseases	Clinical trial 192 participants	Significant reduction in C-reactive protein (CRP) levels and proinflammatory markers (TNF- α and IL-6)	[54]
<i>Lactobacillus rhamnosus</i> CRL1505	2014	Respiratory syncytial virus and Influenza virus A/PR/8/34 (H1N1)	Male BALB/c mice	Reduced risk of lung injury and lower virus titer along with modulation of tissue factor and thrombomodulin expression in lungs of infected mice	[63]
<i>Lactobacillus gasseri</i> SBT2055	2014	Influenza virus A/PR/8/34 (H1N1)	Male C57BL/6N mice	Reduced virus load and lower expression of IL-6 in the lung tissue. Increased expression of myxovirus resistance 1 (Mx1) and oligoadenylate synthetase 1A (Oas1a) resulted in viral clearance	[27]
<i>Lactobacillus casei</i> DN 114001	2014	Antibiotic-associated diarrhea	Clinical trial 258 participants	Probiotics proved to be effective in the treatment of antibiotic-associated diarrhea in both children and adults	[43]
<i>Lactobacillus rhamnosus</i> , <i>Lactobacillus plantarum</i> , and <i>Bifidobacterium longum</i>	2014	Ventilator-associated pneumonia	Clinical trials 1083 participants	Cochrane meta-analysis review of 8 different trials reported the beneficial role of probiotic strains in reducing the risk of ventilator-associated pneumonia	[47]

(continued on next page)

Table 1 (continued)

Probiotic strains	Study year	Infection	Model	Outcomes	Ref.
<i>Lactobacillus reuteri</i> Protectis	2016	Coxsackieviruses and Enterovirus 71 strain 41	Human rhabdomyosarcoma and Caco-2 cell lines	<i>In vitro</i> assays confirmed significant dose-dependent antiviral activity Coxsackievirus type A and Enterovirus 71	[30]
<i>Lactobacillus rhamnosus</i> M21	2016	Influenza virus A/NWS/33 (H1N1)	Female BALB/c mice	The increased survival rate, lower viral titer in lungs of infected mice, and increased production of IFN- γ , IL-2, and IgA	[29]
<i>Lactobacillus rhamnosus</i> HN001, <i>Lactobacillus acidophilus</i> DDS-1, <i>Bifidobacterium lactis</i> Bb-12, and <i>Streptococcus thermophilus</i>	2016	Upper respiratory tract infection	Clinical trials 6269 participants	A meta-analysis of 23 trials reported that consumption of probiotics reduced the prevalence of respiratory tract infections along with the improved quality of life	[50]
<i>Enterococcus faecalis</i>	2017	Influenza virus (A/WSN/33) and Enterovirus 71	Male C57BL/6 mice	Improved survival rate and low viral load in the bronchoalveolar lavage of infected mice	[31]
<i>Lactobacillus acidophilus</i> , <i>Lactobacillus reuteri</i> , and <i>Lactobacillus salivarius</i>	2017	Influenza virus A/Duck/Czech/56 (H4N6)	Madin-Darby canine kidney cells	Enhanced antiviral activity of chicken macrophages. Significantly higher expression of IL-1 β , IFN- γ , and IFN- α resulted in protective responses against infection	[33]
<i>Lactobacillus casei</i> DK128	2017	Influenza virus A/Philippines/2/1982 (H3N2)	Female BALB/c mice	Prevented weight loss and along with higher survival rate and lower expression of IL-6 and TNF- α inflammatory cytokines	[18]
<i>Bacillus subtilis</i> 3	2017	Influenza virus A/FM/1/47 (H1N1)	BALB/c mice	Reduced viral load in lungs and increased survival rate of infected mice	
<i>Lactobacillus paracasei</i> N1115	2017	Upper respiratory tract infection	Clinical trial 233 participants	Reduced provenance of upper respiratory tract infections along with a higher percentage of CD3 ⁺ cells	[51]
<i>Lactobacillus casei</i> strain Shirota	2017	Upper respiratory tract infection	Clinical trial 96 participants	Healthy subjects reported a significantly lower (22.4%) incidence of respiratory infections than 53.2% in the control group.	[52]
<i>Lactobacillus plantarum</i>	2018	H1N1 and H3N2	Female BALB/c mice	Increased survival rate and significantly lower viral proliferation in the lungs of infected mice	[19]
<i>Lactobacillus paracasei</i> , <i>Lactobacillus casei</i> 431, and <i>Lactobacillus fermentum</i> PCC	2018	Upper respiratory tract infection	Clinical trial 136 participants	50% to 60% reduced prevalence of common cold and flu-like symptoms and increased levels of IFN- γ and IgA	[41]
<i>Lactobacillus rhamnosus</i> GG, <i>Lactobacillus reuteri</i> , and <i>Bifidobacterium infantis</i> 35624	2018	Multiple diseases	A meta-analysis of 52 trials	Probiotics were most effective against acute respiratory tract infections, antibiotic-associated diarrhea, acute infectious diarrhea, infant colic, and necrotizing enterocolitis.	[45]
<i>Bifidobacterium bifidum</i>	2019	Influenza virus-A/PR/8/34 (H1N1)	Female BALB/c mice	Increased survival rate along with the induction of both humoral and cellular immune responses	[20]
<i>Lactobacillus gasseri</i> SBT2055	2019	Respiratory syncytial virus-A2 strain	Female BALB/c mice	Reduced weight loss, lower viral load in the lungs of infected mice along with the reduced expression of proinflammatory cytokines	[34]
<i>Lactobacillus rhamnosus</i> GG, <i>Lactobacillus casei</i> , <i>Bifidobacterium lactis</i> Bb-12	2019	Acute respiratory tract infections and acute otitis	A meta-analysis of 17 trials	Probiotic strains significantly reduced the prevalence of common acute infections and antibiotics utilization	[46]

increased secretory IgA production and reduced the expression levels of proinflammatory cytokines TNF- α and IL-6 in lungs of infected mice.

Further, this group's interesting experiment evaluates nine live *Lactobacillus* species against IFV infection. Intranasal administration of probiotic species developed protective efficacy in the mice ranging between 20% and 100%. Among the 9 species, *L. fermentum*-1 and *L. brevis*-2 showed a significantly higher protection rate of 100% and 70% against IFV infection in mice, respectively. These results confirm that *Lactobacillus* species, indeed, has protective efficacy against viral infection, probably by invoking immunomodulatory properties.

A similar but large-scale screening study using 158 probiotic strains concluded that the probiotic strain *L. plantarum* CNRZ1997 is most beneficial against respiratory virus infection/ influenza virus infection in a mouse model [25]. The administration of *L. plantarum* CNRZ1997 led to reduced weight loss, eased clinical symptoms, and inhibited virus proliferation in lungs of infected mice. However, the action mechanism of the probiotic strain was not made clear in this study. In another study, Yamamoto's group [26] evaluated the protective effects of the probiotic strain *L. acidophilus* L-92 against IFV. This strain also effectively prevented weight loss and reduced viral proliferation in lungs of infected mice. Besides, NK T-cells activity was augmented, possibly due to a higher expression of antiviral cytokines and chemokines, which resulted in the prevention of viral infection in mice.

Miyazaki's group [27] performed a study to evaluate the effect of *L. gasseri* SBT2055 probiotic strain against IFV infection in mice. Oral dosage of probiotic bacteria prevented weight loss, significantly reduced virus load in lungs and bronchoalveolar lavage fluids along with decreased inflammatory cytokine IL-6 in the lung tissue. Besides, increased expression of antiviral genes (myxovirus resistance 1) and oligoadenylate synthetase 1A [Oas1a]) resulted in the clearance of viral infection from the lung tissues of infected mice. These results confirm that probiotic bacteria have a pivotal role in the down-regulation of virus replication.

Ha's group [28] investigated 11 probiotic strains belonging to genus *Bifidobacterium* and *Lactobacillus* for their antiviral activity against Human rotavirus Wa (ATCC VR-2018) using Vero cells isolated from monkey kidney. In this *in vitro* experiment, the activity of each probiotic strain was determined by plaque reduction assay. Amongst the tested bacterial strains, *B. longum* and *L. acidophilus* displayed the high inhibitory activity of 38% and 31%, followed by *L. reuteri* with 28%, as evident from a reduced plaque formation. Further, this group also reported that the administration of 6 probiotic strains *B. longum*, *B. lactis*, *L. acidophilus*, *L. rhamnosus*, *L. plantarum*, and *Pediococcus pentosaceus* significantly reduced the duration of diarrhea in pediatric patients without adverse effects. These findings suggest that probiotics consumption can be an alternative therapy for the treatment of acute rotaviral gastroenteritis.

Park's group [29] analyzed the protective effect of probiotic strain *L. rhamnosus* M21 against IFV infection using mice as an animal model. The probiotic strain treatment led to an increased survival rate (~40%) compared to the control group. Pathological results confirm that probiotic strain successfully reduces chronic damage to the lung tissue of infected mice. Probiotic strain administration also resulted in significantly

increased production of IFN- γ , IL-2, and secretory IgA. This study demonstrates that probiotic strain is responsible for activating immune responses and curing the mice against severe virus infection.

The *in vitro* assays results were employed to confirm the antiviral activity of probiotic bacteria *L. reuteri* Protectis and *L. casei* Shirota against Coxsackieviruses and Enterovirus 71 (EV71) [30] infected Human rhabdomyosarcoma and Caco-2 cell lines. The results showed the dose-dependent protective efficacy of *L. reuteri* Protectis against Coxsackievirus type A (strain 6 and 16) and EV71. In another study by Shih's group [31], probiotic bacteria *Enterococcus faecalis* successfully reduced the pathogenicity of EV71 and IFV infections in the mice.

Bacillus genus probiotic bacteria are responsible for producing a wide variety of antimicrobial peptides [32]. Following this, Sorokulova's group [17] conducted a study to evaluate the efficacy of the probiotic strain *Bacillus subtilis* 3 (UCM B-5007) against the influenza virus. Probiotic strain administration resulted in the inhibition of virus replication and increased the survival rate of infected mice. Further, an oral administration of isolated P18 peptide effectively protected 80% of infected mice and significantly lowered viral load in lungs of infected mice. Also, clinical studies on peptide P18 could validate it as a potential antiviral agent.

In an exciting experiment, Kang's group [18] investigated the effect of heat-killed probiotic strain *L. casei* DK128 against influenza H3N2 virus. Intranasal administration of probiotic strain in BALB/c mice resulted in lower weight loss and 100% survival of the infected mice at the end of the study. They observed lower expression of IL-6 and TNF- α inflammatory cytokines and the reduced virus load in lungs of infected mice. This study suggests that heat-killed probiotic strains can be a promising prospect as an antiviral agent.

Recently, Sharif's group [33] elucidated the role of probiotic *Lactobacillus* species in macrophages activation against avian influenza virus infection. They administered chicken macrophage cell-line (MQ-NCSU cells) with three *Lactobacillus* strains (*L. acidophilus*, *L. reuteri*, and *L. salivarius*, respectively) individually or in different combination dosage. As observed, the combination approach induced an antiviral response in the chicken macrophages. It led to a significant reduction in the viral load validated by *in vitro* model (Madin-Darby canine kidney epithelial cells). Combination dosage is known to increase the expression of inflammatory cytokines (IL-1 β , IFN- γ , IFN- α), interferon regulatory factor-7, and 2', 5'-oligoadenylate synthetase (OAS) genes. These results suggest that *Lactobacillus* probiotic strains can effectively augment immune responses, crucial for defense mechanisms against viruses. In compliance with this study, Park's group [19] demonstrated that the probiotic strain *L. plantarum* is effective against influenza A virus (H1N1 and H3N2) infection. Oral administration of heat-killed bacteria led to increased survival rates and significantly reduced virus load in lungs of infected mice.

Miyazaki's group [34] evaluated the efficacy of the probiotic strain *L. gasseri* SBT2055 against the respiratory syncytial virus. Oral administration of the probiotic strain in mice resulted in reduced proinflammatory cytokines and significantly lowered viral load in the lungs. They also reported that SWI2/SNF2-related CREB-binding protein activator protein (SRCAP) was re-

sponsible for virus proliferation. Suppression of SRCAP scaffold protein by the probiotic strain was crucial in inhibiting the virus's binding, leading to a decreased virus load in lungs of infected mice. This recent study provides an insight into the mechanism of probiotic strain as an antiviral agent.

Ghaemi's group [20] elucidated the crucial role of probiotic bacteria *B. bifidum* in activating immune responses against IFV infection using mice as an animal model. Probiotic bacteria administration elicited cellular and humoral immune responses by increasing lymphocyte proliferation and IgG antibodies (IgG1 and IgG2a), respectively. Higher expression of influenza-specific cytokines IFN- γ , IL-12, and IL-4, along with increased survival rate (~80%) of mice, was also reported. This study sheds light on probiotic bacteria's essential role in activating balanced Th1/Th2 immune responses against viral infection. Apart from preventing respiratory viral infections, probiotics administration was also effective against the Hepatitis C virus, Herpes Simplex Virus type 1, Human immunodeficiency virus, Newcastle disease, and infectious bursal disease viruses [35–38].

2.2. Clinical studies in human subjects

Probiotic bacteria play a fundamental role in strengthening immune responses and disease relief in the human host by modulating the balance between proinflammatory and anti-inflammatory cytokines [39,40]. Dannelly's group [41] conducted a double-blinded, placebo-controlled trial of the probiotic mixture containing *L. paracasei*, *L. casei* 431, and *L. fermentum* PCC on patients affected with the common cold and influenza-like respiratory infections. In this trial, among 136 subjects enrolled, 68 subjects were administered probiotic combinations, and the remaining 68 were kept on placebo daily for 12 weeks. The probiotic combination reduced the prevalence of common cold and flu-like symptoms by 50% to 60% compared to the placebo group. Subjects also had higher interferon-gamma (IFN- γ) in the serum and sIgA in the gut in the probiotic-treated group. Increased levels of IFN- γ can induce functions of macrophages and exerts different immunomodulatory actions, which may be responsible for reduced flu-like symptoms. Overall, in this study, no side effects were reported, suggesting that probiotics are safe and effective for combating upper respiratory infections. Isolauri's group [42] performed a double-blinded, placebo-controlled trial to investigate probiotics' effect in reducing the risk of acute infections in infants. In this study, infants were administered probiotic strains *L. rhamnosus* GG and *B. lactis* Bb-12 daily until they reached 12 months. Indeed, infants receiving probiotic supplementation had a significantly reduced risk (28%) of recurrent respiratory infections than the control group (55%). The similar role of probiotic bacteria strain *L. casei* DN 114001 in treating antibiotic-associated diarrhea in both children and adults is also seen by Dietrich's group [43]. A double-blind, placebo-controlled study to analyze the effect of probiotic strain *B. animalis* subsp. *lactis* BB-12 in reducing the risk of acute infectious diseases in newborn infants also had similar encouraging findings. Out of 109 enrolled infants, 55 were administered probiotic bacteria while 54 were on placebo twice a day up to 8 months. Only 65% of infants in the treated

group developed respiratory infections than 94% of infants in the control group. Therefore, infants receiving probiotics had a lower incidence of respiratory diseases [44].

Interestingly, a meta-analysis of 52 randomized controlled trials identified probiotics effective against as many as five diseases, namely acute respiratory tract infections, antibiotic-associated diarrhea, acute infectious diarrhea, infant colic, and necrotizing enterocolitis [45]. It stated that probiotics beneficial effects are through multifactorial mechanisms, including bacterial adhesion inhibition, improved mucosal barrier function, and immune responses modulation. In another meta-analysis of 17 randomized controlled trials, Merenstein's group [46] illustrated that consumption of single or combination dosage of *Lactobacillus* and *Bifidobacterium* probiotic strains significantly reduced the prevalence of common acute infections and antibiotics use among infants and children. In a Cochrane Library systematic review, Deng's group [47] reported that probiotic strains (*L. rhamnosus*, *L. plantarum*, and *B. longum*) reduced the risk of ventilator-associated pneumonia. Another Cochrane review also suggests the crucial role of probiotics in counteracting acute upper respiratory tract infections [48]. Touger-Decker's group [49] conducted a short trial of 12 weeks to evaluate the efficacy of probiotic strains (*L. rhamnosus* GG and *B. lactis* Bb-12) in improving the quality of life in patients affected by upper respiratory infections. In this study, 231 subjects were enrolled, out of which 114 subjects were administered probiotic strains, and the remaining 117 subjects received a placebo for 12 weeks. The severity of upper respiratory infections was 34% lower in the probiotic group than the placebo group. Consumption of probiotic dosage also resulted in improved quality of life of patients without any adverse effects. According to the above studies, Zhang's group [50] reported a meta-analysis of 23 randomized controlled trials involving 6269 patients. As noted, subjects supplemented with probiotic strains had a significantly lower risk of respiratory tract infections and improved quality of life than the placebo group subjects.

Recently, He's group [51] conducted a trial on middle-aged and older adults to evaluate the protective effect of yogurt supplemented with probiotic bacteria (*L. paracasei* N1115) against upper respiratory tract infections. In this study, 233 subjects were randomized in 2 groups to receive either yogurt supplemented with probiotic bacteria ($n = 115$) or the control group ($n = 118$) on a regular diet for 12 weeks. Only 30% of the probiotic group subjects were diagnosed with upper respiratory tract infections compared with 44% in the control group. They did not find any significant difference in the CD4⁺, CD8⁺, total protein, albumin, and pre-albumin levels between the two groups, albeit the probiotic group showed increased CD3⁺ cells. Ishikawa's group [52] investigated probiotics efficacy in preventing upper respiratory tract infections in healthy middle-aged office workers. In this study, 96 subjects with age group 30 to 49 years were enrolled, during winter season once daily up to 12 weeks, 49 subjects consumed *L. casei* strain Shirota-fermented milk and 47 subjects were in control milk group. As reported, respiratory infections were significantly lower (22.4%) in healthy subjects than the 53.2% infection rate in the control group.

Treatment with *L. reuteri* ATCC 55730 enhanced the mucosal expression level of IL-10 and reduced the inflammatory

cytokine expression, including TNF- α , IL-1 β , and IL-8 [53]. In another study, Quigley's group [54] demonstrated that administration of probiotic bacteria *B. infantis* 35624 resulted in immune modulation with a significant reduction in C-reactive protein levels and proinflammatory markers (TNF- α and IL-6) in patients suffering from gastrointestinal tract infections. Bibiloni's group [55] reported the efficacy of VSL#3 in the treatment of patients suffering from clinical remission of ulcerative colitis. VSL#3 is a probiotic mixture of eight strains that modulate the secretion of the anti-inflammatory cytokine, IL-10, and inhibit the secretion of IL-6, IL-8, TNF- α , and IFN γ [56–58]. Thus, probiotics consumption strengthens gut barrier integrity and improves inflammatory responses by various signaling pathways, which can play a pivotal role in curing or preventing human host diseases.

3. Clinical manifestations of SARS-CoV-2 infection

About SARS-CoV-2, the human-to-human transmission mainly occurs via respiratory droplets [2,64]. During cellular entry, SARS-CoV-2 utilizes its spike (S) glycoprotein to bind with angiotensin-converting enzyme 2 receptors present on human host epithelial cells [9]. The type 2 alveolar epithelial cells present in the human gastrointestinal tract, lungs, heart, and kidney [65]. Thus, type 2 alveolar epithelial cells act as a reservoir for virus proliferation and replication. Human lungs are having large surface areas covered with alveolar epithelial type 2 cells, which could be the reason for its higher vulnerability to COVID-19 infection as compared to other body organs. Coronavirus penetration into the lung tissue is responsible for eliciting local inflammatory responses and the disease's manifestations [65]. Disease progression leads to an imbalance in redox homeostasis and an abrupt increase in free radicals, leading to cell damage [66]. The serum of COVID-19 patients has elevated proinflammatory cytokines TNF α , IFN γ , IL-2, IL-6, IL-7, and granulocyte colony-stimulating factor (G-CSF). A few other abnormal findings, such as cellular immune deficiency, renal injury, myocardial injury, hepatic injury, and increased C-reactive protein levels, were observed [67–69]. Therefore, the induction of proinflammatory “cytokine storm” is the root cause behind chronic inflammation in the human host.

During “cytokine storm,” increased circulating levels of proinflammatory cytokines and chemokines cause acute respiratory distress syndrome. In this scenario, aberrant systemic inflammatory responses are augmented in the human body, which causes damage to multiple organs, including lungs, heart, kidney, and liver, leading to organ-exhaustion and finally death [70,71]. Furthermore, COVID-19 infection is also associated with the gut microbiota's dysbiosis, leading to the abundance of pathogenic bacteria in the human host. Recent studies on COVID-19 patients from Zhejiang province (China) reported gastrointestinal tract infections such as nausea, vomiting, or diarrhea [72]. SARS-CoV-2 viral RNA is detected in the stomach, duodenum, esophagus, rectum, and fecal specimens of patients [9,73]. The abrupt production of cytokines is triggered by COVID-19 disease. Additionally, the mucosa's excessive viral load alters gut microflora, leading to loss

of gut barrier integrity and chronic illness in the human host [9,39].

4. Potential preventive application of probiotics in COVID-19 management

While vaccines and drug regimens to manage COVID-19 are awaited, balancing the immune responses and enhancing host immunity is paramount in this present pandemic scenario. Probiotics consumption increases immunological protection in the human host through balancing immune responses (Th1/Th2) and has a potential role in preventing or alleviating various disease pathologies [74–76]. Thus, probiotics intervention in managing viral infections like COVID-19 is plausible. As clear from Table 1, probiotic strains belonging to *Lactobacillus* and *Bifidobacterium* genera both possess general immune-enhancing and antiviral activities. Upon careful analysis of murine experimental data, survival rate, relative lowering of viral load, relative increase in proinflammatory cytokine levels/ anti-inflammatory cytokine levels, disease symptom alleviation, we identify microbial strains suitable to relieve symptoms typical of COVID 19. According to the literature, *L. rhamnosus* CRL1505, *L. gasseri* SBT2055, *L. casei* DK128, *B. bifidum*, and *B. subtilis* 3 appear as promising probiotics to explore further in the management of SARS-CoV-2 infection [17,34]. While *L. gasseri* SBT2055, *L. casei* DK128, and *B. subtilis* 3 strains exhibited the highest survival rate in the mouse model (50–80%), *L. rhamnosus* CRL1505, *L. gasseri* SBT2055, and *B. bifidum* strains induced the most potent anti-inflammatory response [18,[20],27,34]. Insights from clinical studies and human trials suggest that probiotic strains *L. rhamnosus* GG, *L. casei*, *L. plantarum*, *L. casei* strain Shirota, *B. lactis* Bb-12, and *B. longum* significantly reduced the prevalence of upper respiratory infections, common cold, flu-like symptoms, and antibiotic-associated diarrhea by 40% to 70% [42,46,49]. Furthermore, probiotics strains such as *L. reuteri* ATCC 55730, *L. paracasei*, *L. casei* 431, *L. fermentum* PCC, and *B. infantis* 35624 were pivotal in producing immunomodulatory responses during various infections [41,51,53]. The snapshot of the efficacy of probiotic strains as antiviral agents is presented in Fig. 1. As discussed already, SARS-CoV-2 infection leads to a “cytokine storm” that deteriorates patients' lung condition. Therefore, these probiotic strains may facilitate mitigation of “cytokine storm” by balancing cellular and humoral immune responses as seen in experimental animal models. Probiotic bacteria have potential antioxidant activity that may play a crucial role in neutralizing free radical species. As reported, probiotic strains *Clostridium butyricum* MIYAIRI 588, *L. plantarum* CAI6, *L. rhamnosus* GG, and VSL#3 can successfully orchestrate redox homeostasis in the host cell, leading to improved total antioxidant capacity [77,78]. This crucial aspect of probiotic bacteria presents a unique opportunity to manage COVID-19 because redox homeostasis is pivotal in inhibiting disease progression. Therefore, the use of above-mentioned probiotic bacteria may be explored against SARS-CoV-2, albeit detailed research with a different combination of probiotic strains and specific effect on the virus is necessary for the implementation.



Fig. 1 – Shortlist of probiotic strains based on preclinical studies on mice (A) and clinical studies in humans (B) of high relevance to COVID-19 infection management.

5. Proposed mechanism(s) of immune-modulation by probiotic bacteria during coronavirus infection

Various experimental studies have demonstrated the beneficial role of probiotic interventions in combating viral infections. The studies have also stated that probiotic bacteria act by multifactorial mechanisms to enhance antiviral immunity in the host (Fig. 2). Accordingly, while promising probiotic strains are listed above, it is important to understand the probable mechanism of action of probiotic strains in the cellular milieu. Probiotic bacteria can hinder the adsorption process via directly binding to the virus and inhibiting entry into epithelial cells. In coronavirus, probiotic bacteria can also bind to the mucosal epithelial surfaces, resulting in steric

hindrance and blocking the attachment of viruses to angiotensin-converting enzyme 2 like host cell receptor. The colonization of probiotic bacteria plays a pivotal role in improving gut microbiota, strengthening the mucosal barrier, and managing dysbiosis and diarrhea symptoms. Bacteria release diverse substances such as bacteriocins, biosurfactants, lactic acid, hydrogen peroxide, nitric oxide, and organic acids, some or all of which may inhibit virus proliferation [79-81]. Release of intestinal mucins from mucosal cells and secretory antibodies like IgA can also effectively neutralize the coronavirus attack. Upon virus attack in epithelial cells, probiotic bacteria have a crucial role in antiviral immunity via modulation of host immunological responses, including activation of NK cells, balancing Th1/Th2-mediated immunity, production of inflammatory cytokines, and specific antibodies [82-84]. Activation of immune response leads to




Fig. 2 – Schematic depiction of putative mechanisms by which probiotics may help manage coronavirus infection. (A) Probiotic bacteria can hinder the adsorption process via directly binding to the virus and inhibiting entry into epithelial cells. **(B)** Binding of probiotic bacteria to the epithelial surface can cause steric hindrance and block the virus's attachment to the host cell receptor. **(C)** Probiotic bacteria releases antimicrobial substances (such as bacteriocins, biosurfactants, lactic acid, hydrogen peroxide, nitric oxide, organic acids) and intestinal mucins from mucosal cells, which can effectively inhibit virus proliferation. **(D)** Virus neutralized by secretory antibodies like IgA. **(E)** Upon virus attack in epithelial cells, probiotics mediate their antiviral effects by eliciting immune responses by activating macrophages and dendritic cells. **(F)** Activation of immune response leads to differentiating CD8⁺ T lymphocytes into CTLs, capable of destroying virus-infected cells. **(G)** CD4⁺ T lymphocytes cells differentiate into Th1, which activates phagocytosis through NK cells and macrophages, promoting pathogen killing. **(H)** CD4⁺ cells differentiate into Th2 cells, which induce B-cells' proliferation that produces antibodies like IgA, IgG, and IgM. CTLs, cytotoxic T-lymphocytes; Th1, T-helper cells type 1.

the differentiation of CD8⁺ T-lymphocytes into cytotoxic T-lymphocytes, capable of destroying virus-infected cells. Next, CD4⁺ T-lymphocytes cells can differentiate into Th1, which activates phagocytosis through NK cells and macrophages, promoting pathogen killing. Further, CD4⁺ cells differentiate into Th2 cells, which induce B-cells proliferation, resulting in the production of antibodies that may play a crucial role in combating coronavirus proliferation. Thus, probiotic bacteria may catalyze useful immune responses and improve immune homeostasis in coronavirus-infections.

6. Conclusions and future perspectives

Respiratory viral infections are one of the fastest escalating global disease burdens with high mortality rates. The disease severity can range from mild upper tract airway infection to severe chronic inflammation of the mucosal layer in the respiratory tract and multiorgan failure in some patients. At this point, the SARS-CoV-2 pandemic has caused severe mortality in several countries, and yet no precise drug regimen is available to the world population. Improving/strengthening human host immunity is one of the best prophylactic approaches to reduce the severity of such viral diseases. Probiotics have numerous benefits such as balancing the composition of human gut microflora, strengthening gut barrier function, and

protective immune responses. Therefore, multicentric clinical trials with a large number of COVID-19 patients should be performed, which can provide experimental data regarding the role of probiotics supplementation in disease alleviation and improvement in the quality of life in patients along with current therapy. In this context, this review provides extensive literature-backed evidence of the antiviral efficacy of several probiotic strains.

Many viral infections are associated with dysbiosis of gut microbiota leading to severe gastrointestinal tract infections. Thus, the role of probiotics-based therapy becomes pivotal in the management of viral infections. Probiotics can modulate host immune responses and counteract the "cytokine storm" produced during COVID-19 infection. However, using a probiotics-based strategy against COVID-19 infection in clinical and medicinal fields is still an open research question. How to select bacterial species (alone or in combination dosage) which may serve best against the current pandemic situation? How will human host gut microbiota respond to the new bacterial communities in order to tackle viral infections? How to select standard bacterial species for a population, since various complicated factors, such as age, lifestyle, dietary habits, and genetics, influence the human gut microbiota. Deciphering the microbiota composition of COVID-19 patients is also an essential aspect of such study as it may add new dimensions to unravel the infection mechanism and disease progression.

Acknowledgment

The authors would like to acknowledge CSIR for financial support (Project No. MLP021 and MLP040, MLP041). We sincerely thank Dr. Tejinder Kaur for critical reading of the manuscript. The authors declare no conflict of interest.

REFERENCES

- [1] Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet North Am Ed* 2020;395:470–3.
- [2] Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (covid-19): a review of clinical features, diagnosis, and treatment. *Cureus* 2020;12:e7355.
- [3] Cevik M, Bamford C, Ho A. Covid-19 pandemic-a focused review for clinicians. *Clin Microbiol Infect* 2020 <https://doi.org/doi:10.1016/j.cmi.2020.04.023>.
- [4] Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y. Effectiveness of convalescent plasma therapy in severe Covid-19 patients. *Proc Natl Acad Sci* 2020;117:9490–6.
- [5] Lu H. Drug treatment options for the 2019-new coronavirus (2019-ncov). *Bioscience trends* 2020;14:69–71.
- [6] Shanmugaraj B, Siri wattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for coronavirus disease-19 (COVID-19). *Asian Pac J Allergy Immunol* 2020;38:10–18.
- [7] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-ncov) in vitro. *Cell Res* 2020;30:269–71.
- [8] Sadiq FA. Is it time for microbiome-based therapies in viral infections? *Virus Res* 2020;291:198203.
- [9] Antunes AEC, Vinderola G, Xavier-Santos D, Sivieri K. Potential contribution of beneficial microbes to face the covid-19 pandemic. *Food Res Int* 2020;136:109577.
- [10] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al: Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis* 2020;[https://doi.org/10.1016/S1473-3099\(1020\)30243-30247](https://doi.org/10.1016/S1473-3099(1020)30243-30247).
- [11] Munoz-Carrillo JL, Contreras-Cordero JF, Gutierrez-Coronado O, Villalobos-Gutierrez PT, Ramos-Gracia LG, VE Hernaindez-Reyes. Cytokine profiling plays a crucial role in activating immune system to clear infectious pathogens; Immune response activation and immunomodulation. *IntechOpen* 2018. doi:10.5772/intechopen.80843.
- [12] Cytokines in the balance. *Nat Immunol* 2020;20:1557.
- [13] Wieers G, Belkhir L, Enaud R, Leclercq S, Philippart de Foy J-M, et al. How probiotics affect the microbiota. *Front Cell Infect Microbiol* 2020;9:454.
- [14] Hardy H, Harris J, Lyon E, Beal J. Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. *Nutrients* 2013;5:1869–912.
- [15] Al Kassaa I. New insights on antiviral probiotics: From research to applications. Springer; 2017.
- [16] Kawashima T, Hayashi K, Kosaka A, Kawashima M, Igarashi T, Tsutsui H, et al. *Lactobacillus plantarum* strain yu from fermented foods activates Th1 and protective immune responses. *Int Immunopharmacol* 2011;11:2017–24.
- [17] Starosila D, Rybalko S, Varbanetz L, Ivanskaya N, Sorokulova I. Anti-influenza activity of a *Bacillus subtilis* probiotic strain. *Antimicrob Agents Chemother* 2017;61:e00539-00517.
- [18] Jung Y-J, Lee Y-T, Le Ngo V, Cho Y-H, Ko E-J, Hong S-M, et al. Heat-killed *Lactobacillus casei* confers broad protection against influenza a virus primary infection and develops heterosubtypic immunity against future secondary infection. *Sci Rep* 2017;7:1–12.
- [19] Park S, Kim JI, Bae J-Y, Yoo K, Kim H, Kim I-H, et al. Effects of heat-killed *Lactobacillus plantarum* against influenza viruses in mice. *J Microbiol* 2018;56:145–9.
- [20] Mahooti M, Abdolalipour E, Salehzadeh A, Mohebbi SR, Gorji A, Ghaemi A. Immunomodulatory and prophylactic effects of *Bifidobacterium bifidum* probiotic strain on influenza infection in mice. *World J Microbiol Biotechnol* 2019;35:91–8.
- [21] Lehtoranta L, Pitkaranta A, Korpela R. Probiotics in respiratory virus infections. *Eur J Clin Microbiol Infect Dis* 2014;33:1289–302.
- [22] Botić T, Dana T, Weingartl H, Cencia A. A novel eukaryotic cell culture model to study antiviral activity of potential probiotic bacteria. *Int J Food Microbiol* 2007;115:227–34.
- [23] Kanauchi O, Andoh A, AbuBakar S, Yamamoto N. Probiotics and paraprobiotics in viral infection: clinical application and effects on the innate and acquired immune systems. *Curr Pharm Des* 2018;24:710–17.
- [24] Youn H-N, Lee D-H, Lee Y-N, Park J-K, Yuk S-S, et al. Intranasal administration of live *Lactobacillus* species facilitates protection against influenza virus infection in mice. *Antiviral Res* 2012;93:138–43.
- [25] Kechaou N, Chain F, Gratadoux J-J, Sb Blugeon, Bertho N, Chevalier C, et al. Identification of one novel candidate probiotic *Lactobacillus plantarum* strain active against influenza virus infection in mice by a large-scale screening. *Appl Environ Microbiol* 2013;79:1491–9.
- [26] Goto H, Sagitani A, Ashida N, Kato S, Hirota T, Shinoda T, et al. Anti-influenza virus effects of both live and non-live *Lactobacillus acidophilus* l-92 accompanied by the activation of innate immunity. *Br J Nutr* 2013;110:1810–18.
- [27] Nakayama Y, Moriya T, Sakai F, Ikeda N, Shiozaki T, Hosoya T, et al. Oral administration of *Lactobacillus gasseri* SBT2055 is effective for preventing influenza in mice. *Sci Rep* 2014;4:4638.
- [28] Lee HA, Kim H, Lee K-W, Park K-Y. Dead nano-sized *Lactobacillus plantarum* inhibits azoxymethane/dextran sulfate sodium-induced colon cancer in balb/c mice. *J Med Food* 2015;18:1400–5.
- [29] Song JA, Kim HJ, Hong SK, Lee DH, Lee SW, Song CS, et al. Oral intake of *Lactobacillus rhamnosus* M21 enhances the survival rate of mice lethally infected with influenza virus. *J Microbiol Immunol Infect* 2016;49:16–23.
- [30] Ang LYE, Too HKI, Tan EL, Chow T-KV, Shek P-CL, Tham E, et al. Antiviral activity of *Lactobacillus reuteri* protectis against coxsackievirus a and enterovirus 71 infection in human skeletal muscle and colon cell lines. *Virology* 2016;13:111.
- [31] Chen MF, Weng KF, Huang SY, Liu YC, Tseng SN, Ojcius DM, et al. Pretreatment with a heat-killed probiotic modulates monocyte chemoattractant protein-1 and reduces the pathogenicity of influenza and enterovirus 71 infections. *Mucosal Immunol* 2017;10:215–27.
- [32] Sumi CD, Yang BW, Yeo I-C, Hahm YT. Antimicrobial peptides of the genus *Bacillus*: a new era for antibiotics. *Can J Microbiol* 2015;61:93–103.
- [33] Shojadoost B, Kulkarni RR, Brisbin JT, Quinteiro-Filho W, Alkie TN, Sharif S. Interactions between *Lactobacilli* and chicken macrophages induce antiviral responses against avian influenza virus. *Res Vet Sci* 2019;125:441–50.
- [34] Eguchi K, Fujitani N, Nakagawa H, Miyazaki T. Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium *Lactobacillus gasseri* SBT2055. *Sci Rep* 2019;9:1–11.
- [35] An HM, Lee DK, Kim JR, Lee SW, Cha MK, Lee KO, et al. Antiviral activity of *Bifidobacterium adolescentis* SPM 0214 against herpes simplex virus type 1. *Arch Pharm Res* 2012;35:1665–71.

- [36] Abdelhamid AG, El-Masry SS, El-DougDoug NK. Probiotic *Lactobacillus* and *Bifidobacterium* strains possess safety characteristics, antiviral activities and host adherence factors revealed by genome mining. *EPMA J* 2019;10:337–50.
- [37] Patel AR, Shah NP, Prajapati JB. Immunomodulatory effects of probiotics in the treatment of human immunodeficiency virus (HIV) infection. *Biomed Prevent Nutr* 2014;4:81–4.
- [38] Allam NG, Salem ML, Elbatae H, Nabieh MM. *Lactobacillus acidophilus* and *bifidobacteria* spp having antibacterial and antiviral effects on chronic hcv infection. *African J Microbiol Res* 2019;13:77–90.
- [39] Infusino F, Marazzato M, Mancone M, Fedele F, Mastroianni CM, Severino P, et al. Diet supplementation, probiotics, and nutraceuticals in sars-cov-2 infection: a scoping review. *Nutrients* 2020;12:1–21.
- [40] Sundararaman A, Ray M, Ravindra PV, Halami PM. Role of probiotics to combat viral infections with emphasis on COVID-19. *Appl Microbiol Biotechnol* 2020;104:8089–104.
- [41] Zhang H, Yeh C, Jin Z, Ding L, Liu BY, Zhang L, et al. Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate. *Synth Systems Biotechnol* 2018;3:113–20.
- [42] Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy—a randomised, double-blind, placebo-controlled study. *Br J Nutr* 2009;101:1722–6.
- [43] Dietrich CG, Kottmann T, Alavi M. Commercially available probiotic drinks containing *Lactobacillus casei* DN-114001 reduce antibiotic-associated diarrhea. *World J Gastroenterol* 2014;20:15837–44.
- [44] Taipale T, Pienihakkinen K, Isolauri E, Larsen C, Brockmann E, Alanen P, et al. *Bifidobacterium animalis* subsp. *Lactis* bb-12 in reducing the risk of infections in infancy. *Br J Nutr* 2011;105:409–16.
- [45] Liu Y, Tran DQ, Rhoads JM. Probiotics in disease prevention and treatment. *J Clin Pharmacol* 2018;58:S164–79.
- [46] King S, Tancredi D, Lenoir-Wijnkoop I, Gould K, Vann H, Connors G, et al. Does probiotic consumption reduce antibiotic utilization for common acute infections? A systematic review and meta-analysis. *Eur J Public Health* 2019;29:494–9.
- [47] Bo L, Li J, Tao T, Bai Y, Ye X, Hotchkiss RS, et al. Probiotics for preventing ventilator-associated pneumonia. *Cochrane Database Syst Rev* 2014;11:CD009066.
- [48] Saeterdal I, Underland V, Nilsen ES. The effect of probiotics for preventing acute upper respiratory tract infections. *Glob Adv Health Med* 2012;1:124–5.
- [49] Smith TJ, Rigassio-Radler D, Denmark R, Haley T, Touger-Decker R. Effect of *Lactobacillus rhamnosus* LGG(r) and *Bifidobacterium animalis* ssp. *lactis* bb-12(r) on health-related quality of life in college students affected by upper respiratory infections. *Br J Nutr* 2013;109:1999–2007.
- [50] Wang Y, Li X, Ge T, Xiao Y, Liao Y, Cui Y, et al. Probiotics for prevention and treatment of respiratory tract infections in children: a systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)* 2016;95:e4509.
- [51] Pu F, Guo Y, Li M, Zhu H, Wang S, Shen X, et al. Yogurt supplemented with probiotics can protect the healthy elderly from respiratory infections: a randomized controlled open-label trial. *Clin Interv Aging* 2017;12:1223–31.
- [52] Shida K, Sato T, Iizuka R, Hoshi R, Watanabe O, Igarashi T, et al. Daily intake of fermented milk with *Lactobacillus casei* strain shirota reduces the incidence and duration of upper respiratory tract infections in healthy middle-aged office workers. *Eur J Nutr* 2017;56:45–53.
- [53] Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, et al. Randomised clinical trial: the effectiveness of *Lactobacillus reuteri* ATCC 55730 rectal enema in children with active distal ulcerative colitis. *Aliment Pharmacol Ther* 2012;35:327–34.
- [54] Groeger D, O'Mahony L, Murphy EF, Bourke JF, Dinan TG, et al. *Bifidobacterium infantis* 35624 modulates host inflammatory processes beyond the gut. *Gut Microbes* 2013;4:325–39.
- [55] Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. *Am J Gastroenterol* 2005;100:1539–46.
- [56] Chapman TM, Plosker GL, Figgitt DP. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. *Drugs* 2006;66:1371–87.
- [57] Isidro RA, Lopez A, Cruz ML, Gonzalez Torres MI, Chompre G, Isidro AA, et al. The probiotic VSL#3 modulates colonic macrophages, inflammation, and microflora in acute trinitrobenzene sulfonic acid colitis. *J Histochem Cytochem* 2017;65:445–61.
- [58] Hui W, Shuhua LI, Houzhong LI, Fengxia DU, Jie G, Yanmin WU. Mechanism of probiotic VSL#3 inhibiting nf- κ b and tnf- α on colitis through tlr4-nf- κ b signal pathway. *Iran J Public health* 2019;48:1292.
- [59] Izumo T, Maekawa T, Ida M, Noguchi A, Kitagawa Y, Shibata H, et al. Effect of intranasal administration of *Lactobacillus pentosus* s-pt84 on influenza virus infection in mice. *Int Immunopharmacol* 2010;10:1101–6.
- [60] Kawase M, He F, Kubota A, Harata G, Hiramatsu M. Oral administration of *Lactobacilli* from human intestinal tract protects mice against influenza virus infection. *Lett Appl Microbiol* 2010;51:6–10.
- [61] Kobayashi N, Saito T, Uematsu T, Kishi K, Toba M, Kohda N, et al. Oral administration of heat-killed *Lactobacillus pentosus* strain b240 augments protection against influenza virus infection in mice. *Int Immunopharmacol* 2011;11:199–203.
- [62] Kwak M-K, Liu R, Kwon J-O, Kim M-K, Kim AH, Kang S-O. Cyclic dipeptides from lactic acid bacteria inhibit proliferation of the influenza a virus. *J Microbiol* 2013;51:836–43.
- [63] Zelaya H, Tsukida K, Chiba E, Marranzino G, Alvarez S, Kitazawa H, et al. Immunobiotic lactobacilli reduce viral-associated pulmonary damage through the modulation of inflammation-coagulation interactions. *Int Immunopharmacol* 2014;19:161–73.
- [64] Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19); Statpearls [internet. StatPearls Publishing; 2020.
- [65] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of sars coronavirus. *J Virol* 2020;94 e00127–00120.
- [66] Delgado-Roche L, Mesta F. Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection. *Arch Med Res* 2020 <https://doi.org/doi:10.1016/j.arcmed.2020.1004.1019>.
- [67] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet North Am Ed* 2020;395:497–506.
- [68] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. Covid-19: consider cytokine storm syndromes and immunosuppression. *Lancet North Am Ed* 2020;395:1033–4.
- [69] Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020:1–3.

- [70] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of covid-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020;8:420–2.
- [71] Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in covid-19: an overview of the involvement of the chemokine/chemokine-receptor system. *Cytokine Growth Factor Rev* 2020 <https://doi.org/doi:10.1016/j.cytogfr.2020.05.003>.
- [72] Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (Covid-19) with gastrointestinal symptoms. *Gut* 2020;69:1002–9.
- [73] Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Ng SC. Alterations in gut microbiota of patients with covid-19 during time of hospitalization. *Gastroenterology* 2020;159:944–55.
- [74] Kitazawa H, Villena J. Modulation of respiratory tlr3-anti-viral response by probiotic microorganisms: Lessons learned from *Lactobacillus rhamnosus* CRL1505. *Front Immunol* 2014;5:201.
- [75] Azad M, Kalam A, Sarker M, Wan D. Immunomodulatory effects of probiotics on cytokine profiles. *Biomed Res Int* 2018;2018:1–10.
- [76] Zeng W, Shen J, Bo T, Peng L, Xu H, Nasser MI, et al. Cutting edge: probiotics and fecal microbiota transplantation in immunomodulation. *J Immunol Res* 2019;2019:1–17.
- [77] Wang Y, Wu Y, Wang Y, Xu H, Mei X, Yu D, et al. Antioxidant properties of probiotic bacteria. *Nutrients* 2017;9:521.
- [78] Mishra V, Shah C, Mokashe N, Chavan R, Yadav H, Prajapati J. Probiotics as potential antioxidants: a systematic review. *J Agric Food Chem* 2015;63:3615–26.
- [79] Servin AL. Antagonistic activities of *Lactobacilli* and *Bifidobacteria* against microbial pathogens. *FEMS Microbiol Rev* 2004;28:405–40.
- [80] Choi H-J, Song J-H, Ahn Y-J, Baek S-H, Kwon D-H. Antiviral activities of cell-free supernatants of yogurts metabolites against some rna viruses. *Eur Food Res Technol* 2009;228:945–50.
- [81] Pipenbaher Na, Moeller PL, DolinÅ;jek J, Jakobsen M, Weingartl H, CenciÅ A. Nitric oxide (no) production in mammalian non-tumorigenic epithelial cells of the small intestine and macrophages induced by individual strains of *Lactobacilli* and *Bifidobacteria*. *Int Dairy J* 2009;19:166–71.
- [82] Veckman V, Miettinen M, Pirhonen J, Siran J, Matikainen S, Julkunen I. *Streptococcus pyogenes* and *Lactobacillus rhamnosus* differentially induce maturation and production of th1-type cytokines and chemokines in human monocyte-derived dendritic cells. *J Leukoc Biol* 2004;75:764–71.
- [83] Weiss G, Rasmussen S, Zeuthen LH, Nielsen BN, Jarmer H, Jespersen L, et al. Hanne: *Lactobacillus acidophilus* induces virus immune defence genes in murine dendritic cells by a toll-like receptor-2-dependent mechanism. *Immunology* 2010;131:268–81.
- [84] Latvala S, Miettinen M, Kekkonen R, Korpela R, Julkunen I. Potentially probiotic bacteria induce cytokine production and suppressor of cytokine signaling 3 gene expression in human monocyte-derived macrophages. *Cytokine* 2009;48:100–1.